Evidence map›Paper›PMID 32295829›Full record

ArticleJournal of lipid research2020

LDL subclass lipidomics in atherogenic dyslipidemia: effect of statin therapy on bioactive lipids and dense LDL.

M John Chapman, Alexina Orsoni, Ricardo Tan, Natalie A Mellett, Anh Nguyen, Paul Robillard, Philippe Giral, Patrice Thérond, Peter J Meikle

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of lipid research, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed.

  1. Trial
  2. Trial
  3. Review
  4. Review
  5. Article
  6. Article
  7. Assessment of the relationship between AHR, sdLDL, Klotho biomarkers, and etiologic subtypes in young to middle-aged acute ischemic stroke according to toast classification.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2026
    Article
  8. Article
  9. Review
  10. Deciphering Acute Coronary Syndromes Pathobiology Through Proteomics.Journal of cardiovascular development and disease · 2025
    Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Review
  16. Review
  17. Review
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

M John ChapmanEndocrinology Metabolism Division, Pitié-Salpetrière University Hospital, Sorbonne University and National Institute for Health and Medical Research (INSERM), Paris, France; Metabolomics Laboratory Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia. Electronic address: mailto:john.chapman@upmc.fr.
Alexina OrsoniService de Biochimie AP-HP, HU Paris-Saclay, Bicetre University Hospital, Le Kremlin Bicêtre and EA 7357, Paris-Saclay University, Chatenay-Malabry, France.
Ricardo TanMetabolomics Laboratory Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Natalie A MellettMetabolomics Laboratory Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Anh NguyenMetabolomics Laboratory Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.
Paul RobillardEndocrinology Metabolism Division, Pitié-Salpetrière University Hospital, Sorbonne University and National Institute for Health and Medical Research (INSERM), Paris, France.
Philippe GiralINSERM UMR1166 and Cardiovascular Prevention Units, ICAN-Institute of CardioMetabolism and Nutrition, AP-HP, Pitié-Salpetrière University Hospital, Paris, France.
Patrice ThérondService de Biochimie AP-HP, HU Paris-Saclay, Bicetre University Hospital, Le Kremlin Bicêtre and EA 7357, Paris-Saclay University, Chatenay-Malabry, France.
Peter J MeikleMetabolomics Laboratory Baker Heart and Diabetes Institute, Melbourne, Victoria, Australia.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Atherogenic LDL particles are physicochemically and metabolically heterogeneous. Can bioactive lipid cargo differentiate LDL subclasses, and thus potential atherogenicity? What is the effect of statin treatment? Obese hypertriglyceridemic hypercholesterolemic males [n = 12; lipoprotein (a) <10 mg/dl] received pitavastatin calcium (4 mg/day) for 180 days in a single-phase unblinded study. The lipidomic profiles (23 lipid classes) of five LDL subclasses fractionated from baseline and post-statin plasmas were determined by LC-MS. At baseline and on statin treatment, very small dense LDL (LDL5) was preferentially enriched (up to 3-fold) in specific lysophospholipids {LPC, lysophosphatidylinositol (LPI), lysoalkylphosphatidylcholine [LPC(O)]; 9, 0.2, and 0.14 mol per mole of apoB, respectively; all

Indexed as

LipidomicsAtherosclerosisDyslipidemiasFemaleHumansHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins, LDLMaleMiddle AgedHydroxymethylglutaryl-CoA Reductase InhibitorsLipoproteins, LDLceramidesisopycnic density gradient ultracentrifugationlipoprotein-associated phospholipase A2liquid chromatography electrospray ionization-tandem mass spectrometrylow density lipoproteinlow density lipoprotein subclass heterogeneitylysophosphatidylcholinemetabolic syndromepitavastatin calcium

Identifiers

PMID32295829
PMCPMC7269759

What OpenQuestion holds

Texttitle and abstract
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.